FDA Issues Final Rule on Hemp-Derived Delta-9 THC: What It Means for the Industry
The FDA's long-awaited final rule on hemp-derived cannabinoids establishes a 0.3% total THC threshold, bans delta-8 THC in food and beverages, and creates a new regulatory pathway for hemp-derived CBD supplements.
Sarah Chen
Founder & Editor-in-Chief, Cannabis Dispensary
The Food and Drug Administration published its final rule on hemp-derived cannabinoids on April 30, 2026, resolving years of regulatory uncertainty that had allowed an unregulated market in delta-8 THC, delta-10 THC, and other hemp-derived psychoactive compounds to flourish. The rule has significant implications for both the hemp industry and the broader cannabis market.
The Core Problem the Rule Addresses
The 2018 Farm Bill legalized hemp — defined as cannabis with less than 0.3% delta-9 THC on a dry weight basis — and removed it from the Controlled Substances Act. This created a regulatory gap that entrepreneurs exploited by producing delta-8 THC, delta-10 THC, THC-O, and other psychoactive cannabinoids from hemp-derived CBD through chemical conversion processes. These products were sold in gas stations, convenience stores, and online with no age verification, no potency testing, and no regulatory oversight — while state-licensed cannabis dispensaries faced extensive regulation and taxation.
Key Provisions of the Final Rule
The rule establishes a "total THC" standard for hemp products, counting all THC isomers (delta-8, delta-9, delta-10, THCO, THCP, etc.) toward the 0.3% threshold. Products exceeding this threshold are classified as cannabis under the CSA regardless of their source material. This effectively bans the commercial sale of high-potency delta-8 and delta-10 products that have dominated the unregulated hemp market.
The rule creates a new regulatory pathway for hemp-derived CBD as a dietary supplement, resolving the FDA's longstanding position that CBD could not be marketed as a supplement because it was first approved as a drug (Epidiolex). Under the new pathway, CBD supplements must meet Good Manufacturing Practice standards, include accurate labeling, and comply with serving size limits (currently proposed at 30mg/day for general wellness products).
Industry Winners and Losers
The rule is a significant win for state-licensed cannabis operators, who have argued for years that the unregulated hemp market created an unfair competitive advantage. It is a significant loss for the delta-8 THC industry, which had grown to an estimated $2 billion in annual sales. Hemp CBD supplement companies that can meet GMP standards will benefit from the new regulatory clarity.
Enforcement Challenges
The FDA acknowledged significant enforcement challenges. The agency has limited resources for hemp market enforcement and has historically relied on warning letters rather than injunctive action. State attorneys general in several states announced concurrent enforcement actions against delta-8 retailers. The DEA indicated it would treat non-compliant delta-8 products as Schedule I controlled substances.
Consumer Safety Implications
Poison control centers reported a 300% increase in calls related to delta-8 THC products between 2020 and 2025, with a disproportionate number involving children who consumed products packaged to resemble candy or snacks. The FDA cited these data prominently in the rule's preamble as justification for the regulatory action.